IgH-V(D)J NGS-MRD measurement pre-and early post-allotransplant defines very low-and very high-risk ALL patients

Blood

Volumn 125, Issue 22, 2015, Pages 3501-3508

  Pulsipher, Michael A ^a   Carlson, Chris ^b,c   Langholz, Bryan ^d   Wall, Donna A ^e   Schultz, Kirk R ^f   Bunin, Nancy ^g,h   Kirsch, Ilan ^c   Gastier Foster, Julie M ^i,j   Borowitz, Michael ^k   Desmarais, Cindy ^c   Williamson, David ^c   Kalos, Michael ^l   Grupp, Stephan A ^g,h,m  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c ADAPTIVE BIOTECHNOLOGIES   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Manitoba Blood and Marrow Transplant Program   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ NATIONWIDE CHILDREN S HOSPITAL   (United States)

^j THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^k DEPARTMENT OF PATHOLOGY   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN HEAVY CHAIN V(D)J; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; COMPLEMENTARITY DETERMINING REGION; CONFERENCE PAPER; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LEUKEMIA CELL; LEUKEMIA RELAPSE; LOW RISK PATIENT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE RISK; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; CLINICAL TRIAL; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH THROUGHPUT SEQUENCING; INFANT; MORTALITY; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; VDJ EXON; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; INFANT; MALE; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; VDJ EXONS; YOUNG ADULT;

EID: 84930960200     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-12-615757     Document Type: Conference Paper

References (38)

1. Borowitz MJ, Devidas M, Hunger SP, et al; Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-5485.
2. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOPBFM ALL 2000 study. Blood. 2010;115(16): 3206-3214.
3. Pulsipher MA, Langholz B, Wall DA, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood. 2014; 123(13):2017-2025.
4. Bader P, Kreyenberg H, Henze GH, et al; ALLREZ BFM Study Group. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALLREZ BFM Study Group. J Clin Oncol. 2009;27(3): 377-384.
5. Larimore K, McCormick MW, Robins HS, Greenberg PD. Shaping of human germline IgH repertoires revealed by deep sequencing. J Immunol. 2012;189(6):3221-3230.
6. Faham M, Zheng J, Moorhead M, et al. Deepsequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173-5180.
7. Wu D, Emerson RO, Sherwood A, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014;20(17):4540-4548.
8. Pulsipher MA, Chitphakdithai P, Logan BR, et al. Lower risk of serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood. 2014;123(23):3655-3663.
9. Carlson CS, Emerson RO, Sherwood AM, et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun. 2013;4:2680.
10. Borowitz MJ, Wood BL, Devidas M, et al. Improved post-induction chemotherapy does not abrogate prognostic significance of minimal residual disease (MRD) for children and young adults with high risk acute lymphoblastic leukemia (ALL). A report from Children's Oncology Group (COG) Study AALL0232 [abstract]. Blood. 2011; 118(21). Abstract 1440.
11. Dworzak MN, Fröschl G, Printz D, et al; Austrian Berlin-Frankfurt-Munster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99(6): 1952-1958.
12. Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia. 2003;17(8):1566-1572.
13. Aalen OO, Johansen S. An empirical transition matrix for nonhomogeneous Markov chains based on censored observations. Scand J Stat. 1978; 5(3):141-150.
14. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26(24):3913-3915.
15. Pulsipher MA, Langholz B, Wall DA, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase III COG/PBMTC trial [published online ahead of print February 4, 2014]. Blood.
16. Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000;18(2):340-347.
17. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant. 2003;32(6):543-548.
18. Eapen M, Raetz E, Zhang MJ, et al; Children's Oncology Group; Center for International Blood and Marrow Transplant Research. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood. 2006; 107(12):4961-4967.
19. Oliansky DM, Camitta B, Gaynon P, et al; American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant. 2012; 18(4):505-522.
20. Oliansky DM, Camitta B, Gaynon P, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. Biol Blood Marrow Transplant. 2012; 18(7):979-981.
21. Oliansky DM, Larson RA, Weisdorf D, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant. 2012;18(1):16-17.
22. Oliansky DM, Larson RA, Weisdorf D, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant. 2012;18(1):18-36.e6.
23. Socié G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18(2):348-357.
24. Leung W, Ahn H, Rose SR, et al. A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore). 2007;86(4): 215-224.
25. Krull KR, Zhang N, Santucci A, et al. Long-term decline in intelligence among adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation. Blood. 2013;122(4): 550-553.
26. Pulsipher MA, Boucher KM, Wall D, et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood. 2009;114(7):1429-1436.
27. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma: a Children's Oncology Group study [published correction appears in J Clin Oncol. 2008;26(28):4697]. J Clin Oncol. 2008;26(24): 3971-3978.
28. Eckert C, Henze G, Seeger K, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013; 31(21):2736-2742.
29. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3): 555-562.
30. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001; 97(6):1572-1577.
31. Passweg JR, Tiberghien P, Cahn JY, et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;21(2):153-158.
32. Locatelli F, Zecca M, Messina C, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia. 2002;16(11): 2228-2237.
33. Dini G, Zecca M, Balduzzi A, et al; Associazione Italiana Ematologia ed Oncologia Pediatrica-Hematopoietic Stem Cell Transplantation (AIEOP-HSCT) Group. No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood. 2011; 118(25):6683-6690.
34. Davies SM, Wang D, Wang T, et al. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant. 2009;15(3): 360-366.
35. Balduzzi A, Di Maio L, Silvestri D, et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? Br J Haematol. 2014;164(3):396-408.
36. Fronkova E, Muzikova K, Mejstrikova E, et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplant. 2008;42(3): 187-196.
37. Bader P, Kreyenberg H, von Stackelberg A, et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015; 33(11):1275-1284.
38. Logan AC, Vashi N, Faham M, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014; 20(9):1307-1313.